IP Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
International Paper is not a strong buy right now for a beginner long-term investor with $50,000-$100,000 to deploy. The stock has some constructive medium-term support from analyst upgrades, cost-cutting/self-help efforts, and a major new packaging plant investment, but the latest earnings commentary and lowered FY26 outlook show fundamentals are still under pressure. Since you are impatient and want a direct answer, I would not buy aggressively at this moment; I would wait for clearer financial improvement or a better entry.
IP is in a mildly constructive but not decisive trend. Pre-market price is 33.25, slightly below the 33.32 reference and just under R2 at 33.945. MACD histogram is positive and expanding, which supports near-term momentum, but RSI_6 at 69.865 is stretched into the upper range, suggesting limited upside before momentum cools. Moving averages are converging, showing a transition phase rather than a strong confirmed uptrend. Key levels: pivot 31.344, resistance 32.952 and 33.945, support 29.735 and 28.742. Overall, the chart is improving, but not yet a clean long-term entry signal.
["Wells Fargo upgraded IP to Overweight and sees favorable risk/reward after the Q1 selloff.", "Seaport Research upgraded IP to Buy, citing improving competitive position and industry containerboard capacity take-out.", "The company is investing $225 million in a new Mississippi sustainable packaging facility, which supports long-term growth and efficiency.", "News flow suggests continued commitment to supply-chain efficiency and local expansion.", "Technical momentum is improving, with MACD positive and expanding."]
["JPMorgan said Q1 EBITDA missed consensus and Q2 EBITDA guidance is well below expectations.", "FY26 EBITDA guidance was lowered, signaling weaker near-term fundamentals.", "Several firms cut price targets around earnings, showing reduced confidence in the near-term outlook.", "Options positioning is cautious with put-heavy ratios.", "Congress trading shows 3 recent sales and 0 purchases, a negative sentiment signal."]
Latest quarter mentioned is Q1 2026. The quarter was weaker than expected: Q1 EBITDA was $677M, about 3% below consensus and below prior guidance of $740M. Management also lowered FY26 EBITDA guidance to $3.2B-$3.5B from $3.5B-$3.7B, and Q2 EBITDA guidance is about 25% below consensus at the midpoint. That points to slowing growth and pressure on earnings momentum rather than accelerating fundamentals.
Analyst opinion is mixed but leaning cautious-to-positive. Recent upgrades from Wells Fargo and Seaport Research are constructive, while UBS, Citi, JPMorgan, Deutsche Bank, and Truist all lowered price targets. The most recent target range clusters roughly from $32 to $40, showing some upside from the current low-30s price, but the repeated target cuts after earnings indicate Wall Street is still worried about near-term execution. Pros: self-help initiatives, North America improvement, and industry capacity reductions. Cons: weak Q1 results, reduced FY26 guidance, and macro/cost pressure.
